{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:33:25Z","timestamp":1790354005501,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Fatty acid binding protein 5 (FABP5) is elevated in psoriatic keratinocytes and could be involved in systemic metabolic disturbances in psoriasis. The aim of the study was to evaluate serum FABP5 in obese and non-obese psoriatic patients, to assess the relationship between FABP5 and the duration, severity of the disease, inflammatory and metabolic markers and influence of treatment with narrowband\u2014ultraviolet B (NB-UVB). Seventy-four patients (30 treated with NB-UVB) with psoriasis were enrolled in the study. The serum concentrations of FABP5 were measured using Human FABP5 Enzyme-Linked Immunosorbent Assay kit. Serum fatty acids were measured by gas\u2013liquid chromatography. Serum FABP5 levels in psoriatic patients were higher versus control group (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). FABP5 in patients with PASI\u2009&gt;\u200920 was higher compared to the mild group (PASI\u2009&lt;\u200910) (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) and serum FABP5 correlated positively with PASI score (r\u2009=\u20090.41,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). There was also positive correlation between FABP5 and basic inflammation indices. Decrease of PASI after NB-UVB treatment (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) was observed and accompanied by decrease of the serum FABP5 (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.007). FABP5 is a potential marker of psoriasis, its severity and clinical outcome after therapy with NB-UVB. FABP5 may reflect metabolic disturbances in psoriatic patients.\n                  <\/jats:p>","DOI":"10.1007\/s11033-021-06461-3","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T15:02:32Z","timestamp":1623769352000},"page":"4421-4429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Serum fatty acid binding protein 5 (FABP5) as a potential biomarker of inflammation in psoriasis"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1189-0999","authenticated-orcid":false,"given":"Dorota","family":"Koz\u0142owska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"My\u015bliwiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Harasim-Symbor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Justyna","family":"Milewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Chabowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Flisiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"key":"6461_CR1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1365-2133.2007.07986.x","volume":"157","author":"P Gisondi","year":"2007","unstructured":"Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni A (2007) Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 157:68\u201373. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07986.x","journal-title":"Br J Dermatol"},{"key":"6461_CR2","doi-asserted-by":"publisher","first-page":"e0181039","DOI":"10.1371\/journal.pone.0181039","volume":"18","author":"S Singh","year":"2017","unstructured":"Singh S, Young P, Armstrong AW (2017) An update on psoriasis and metabolic syndrome: a meta-analysis of observational studies. PLoS ONE 18:e0181039. https:\/\/doi.org\/10.1371\/journal.pone.0181039","journal-title":"PLoS ONE"},{"key":"6461_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40259-019-00394-x","volume":"34","author":"V Strand","year":"2020","unstructured":"Strand V, Gon\u00e7alves J, Hickling TP, Jones HJ, Marshall L, Isaacs JD (2020) Immunogenicity of biosimilars for rheumatic diseases, plaque psoriasis, and inflammatory bowel disease: a review from clinical trials and regulatory documents. BioDrugs 34:27\u201337. https:\/\/doi.org\/10.1007\/s40259-019-00394-x","journal-title":"BioDrugs"},{"key":"6461_CR4","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jaad.2013.06.053","volume":"69","author":"IM Miller","year":"2013","unstructured":"Miller IM, Ellervik C, Yazdanyar S, Jemec GBE (2013) Meta - analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol 69:1014\u20131024. https:\/\/doi.org\/10.1016\/j.jaad.2013.06.053","journal-title":"J Am Acad Dermatol"},{"key":"6461_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/ajd.13175","volume":"61","author":"J Magdaleno-Tapial","year":"2020","unstructured":"Magdaleno-Tapial J, Valenzuela-O\u00f1ate C, Ortiz-Salvador JM, Mart\u00ednez-Dom\u00e9nech A, Garc\u00eda-Legaz-Mart\u00ednez M, Alonso-Carpio M, Tamarit-Garc\u00eda JJ et al (2020) Prevalence of non-alcoholic fatty liver and liver fibrosis in patients with moderate-severe psoriasis: a cross-sectional cohort study. Australas J Dermatol 61:105\u2013109. https:\/\/doi.org\/10.1111\/ajd.13175","journal-title":"Australas J Dermatol"},{"key":"6461_CR6","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/1744666X.2016.1201423","volume":"12","author":"A Chiricozzi","year":"2016","unstructured":"Chiricozzi A, Raimondo A, Lembo S, Fausti F, Dini V, Costanzo A, Monfrecola G et al (2016) Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Rev Clin Immunol 12:1299\u20131308. https:\/\/doi.org\/10.1080\/1744666X.2016.1201423","journal-title":"Expert Rev Clin Immunol"},{"key":"6461_CR7","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.3390\/ijms20184347","volume":"20","author":"K Kamiya","year":"2019","unstructured":"Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M (2019) Risk factors for the development of psoriasis. Int J Mol Sci 20:4347. https:\/\/doi.org\/10.3390\/ijms20184347","journal-title":"Int J Mol Sci"},{"key":"6461_CR8","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","volume":"31","author":"NN Mehta","year":"2010","unstructured":"Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM (2010) Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. Eur Heart J 31:1000\u20131006. https:\/\/doi.org\/10.1093\/eurheartj\/ehp567","journal-title":"Eur Heart J"},{"key":"6461_CR9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bjd.15021","volume":"176","author":"DA Springate","year":"2017","unstructured":"Springate DA, Parisi R, Kontopantelis E, Reeves D, Griffiths CEM, Ashcroft DM (2017) Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. Br J Dermatol 176:650\u2013658. https:\/\/doi.org\/10.1111\/bjd.15021","journal-title":"Br J Dermatol"},{"key":"6461_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrd2589","volume":"7","author":"M Furuhashi","year":"2008","unstructured":"Furuhashi M, Hotamisligil GS (2008) Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 7:489\u2013503. https:\/\/doi.org\/10.1038\/nrd2589","journal-title":"Nat Rev Drug Discov"},{"key":"6461_CR11","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3390\/jcm8071021","volume":"8","author":"M Sikora","year":"2019","unstructured":"Sikora M, Stec A, Chrabaszcz M, Waskiel-Burnat A, Zaremba M, Olszewska M, Rudnicka L (2019) Intestinal Fatty Acid Binding Protein, a biomarker of intestinal barrier is associated with severity of psoriasis. J Clin Med 8:1021. https:\/\/doi.org\/10.3390\/jcm8071021","journal-title":"J Clin Med"},{"key":"6461_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11745-016-4211-4","volume":"52","author":"A Baran","year":"2017","unstructured":"Baran A, \u015awiderska M, Bacharewicz-Szczerbicka J, My\u015bliwiec H, Flisiak I (2017) Serum fatty acid-binding protein 4 is increased in patients with psoriasis. Lipids 52:51\u201360. https:\/\/doi.org\/10.1007\/s11745-016-4211-4","journal-title":"Lipids"},{"key":"6461_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4161\/derm.3.2.14816","volume":"3","author":"D Khnykin","year":"2011","unstructured":"Khnykin D, Miner JH, Jahnsen F (2011) Role of fatty acid transporters in epidermis: implications for health and disease. Dermatoendocrinol 3:53\u201361. https:\/\/doi.org\/10.4161\/derm.3.2.14816","journal-title":"Dermatoendocrinol"},{"key":"6461_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/1479-7364-5-3-170","volume":"5","author":"RL Smathers","year":"2011","unstructured":"Smathers RL, Petersen DR (2011) The human fatty acid-binding protein family: evolutionary divergences and functions. Hum Genomics 5:170\u2013191. https:\/\/doi.org\/10.1186\/1479-7364-5-3-170","journal-title":"Hum Genomics"},{"key":"6461_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/exd.12111","volume":"22","author":"K Dallaglio","year":"2013","unstructured":"Dallaglio K, Marconi A, Truzzi F, Lotti R, Palazzo E, Petrachi T, Saltari A et al (2013) E-FABP induces differentiation in normal human keratinocytes and modulates the differentiation process in psoriatic keratinocytes in vitro. Exp Dermatol 22:255\u2013261. https:\/\/doi.org\/10.1111\/exd.12111","journal-title":"Exp Dermatol"},{"key":"6461_CR16","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.amjcard.2010.06.028","volume":"106","author":"R Bagheri","year":"2010","unstructured":"Bagheri R, Qasim AN, Mehta NN, Terembula K, Kapoor S, Braunstein S, Schutta M et al (2010) Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus. Am J Cardiol 106:1118\u20131123. https:\/\/doi.org\/10.1016\/j.amjcard.2010.06.028","journal-title":"Am J Cardiol"},{"issue":"3","key":"6461_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000083509","volume":"210","author":"J Schmitt","year":"2005","unstructured":"Schmitt J, Wozel G (2005) The Psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 210(3):194\u2013199. https:\/\/doi.org\/10.1159\/000083509","journal-title":"Dermatology"},{"issue":"8","key":"6461_CR18","doi-asserted-by":"publisher","first-page":"e12045","DOI":"10.1371\/journal.pone.0012045","volume":"5","author":"C Glaser","year":"2010","unstructured":"Glaser C, Demmelmai H, Koletzko B (2010) High-throughput analysis of total plasma fatty acid composition with direct in situ transesterification. PLoS One 5(8):e12045. https:\/\/doi.org\/10.1371\/journal.pone.0012045","journal-title":"PLoS One"},{"key":"6461_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jdermsci.2012.09.002","volume":"68","author":"T Miyake","year":"2012","unstructured":"Miyake T, Ogawa E, Mikoshiba A, Kobayashi A, Hosoe H, Kashiwabara S, Uhara H et al (2012) Epidermal-type FABP is a predictive marker of clinical response to systemic treatment and ultraviolet therapy in psoriatic skin lesions. J Dermatol Sci 68:199\u2013202. https:\/\/doi.org\/10.1016\/j.jdermsci.2012.09.002","journal-title":"J Dermatol Sci"},{"key":"6461_CR20","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1159\/000246367","volume":"192","author":"I Masouye","year":"1996","unstructured":"Masouye I, Saurat JH, Siegenthaler G (1996) Epidermal fatty-acid-binding protein in psoriasis, basal and squamous cell carcinomas: an immunohistological study. Dermatology 192:208\u2013213. https:\/\/doi.org\/10.1159\/000246367","journal-title":"Dermatology"},{"key":"6461_CR21","doi-asserted-by":"publisher","first-page":"7526","DOI":"10.1038\/s41598-019-43899-9","volume":"9","author":"SC Furiati","year":"2019","unstructured":"Furiati SC, Catarino JS, Silva MV, Silva RF, Estevam RB, Teodoro RB, Pereira SL, Ataide M (2019) Th1, Th17, and Treg responses are differently modulated by TNF- \u03b1 inhibitors and methotrexate in psoriasis patients. Sci Rep 9:7526. https:\/\/doi.org\/10.1038\/s41598-019-43899-9","journal-title":"Sci Rep"},{"key":"6461_CR22","doi-asserted-by":"publisher","first-page":"7625","DOI":"10.4049\/jimmunol.0804192","volume":"182","author":"B Li","year":"2009","unstructured":"Li B, Reynolds JM, Stout RD, Bernlohr DA, Suttles J (2009) Regulation of Th17 differentiation by epidermal fatty acid-binding protein. J Immunol 182:7625\u20137633. https:\/\/doi.org\/10.4049\/jimmunol.0804192","journal-title":"J Immunol"},{"key":"6461_CR23","doi-asserted-by":"publisher","first-page":"398","DOI":"10.18632\/oncoscience.54","volume":"1","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Li B (2014) E-FABP: regulator of immune function. Oncoscience 1:398\u2013399. https:\/\/doi.org\/10.18632\/oncoscience.54","journal-title":"Oncoscience"},{"key":"6461_CR24","doi-asserted-by":"publisher","first-page":"7353420","DOI":"10.1155\/2019\/7353420","volume":"2019","author":"C Rodriguez-Cerdeira","year":"2019","unstructured":"Rodriguez-Cerdeira C, Cordeiro-Rodriguez M, Carnero-Gregorio M, Lopez-Barcenas A, Martinez-Herrera E, Fabbrocini G et al (2019) Biomarkers of inflammation in obesity-psoriatic patients. Mediators Inflamm 2019:7353420. https:\/\/doi.org\/10.1155\/2019\/7353420","journal-title":"Mediators Inflamm"},{"key":"6461_CR25","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","volume":"9","author":"WH Boehncke","year":"2018","unstructured":"Boehncke WH (2018) Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol 9:579. https:\/\/doi.org\/10.3389\/fimmu.2018.00579","journal-title":"Front Immunol"},{"key":"6461_CR26","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1093\/eurheartj\/ehn295","volume":"29","author":"DC Yeung","year":"2008","unstructured":"Yeung DC, Wang Y, Xu A, Cheung SCW, Wat NMS, Fong DYT, Fong CHY (2008) Epidermal fatty-acid-binding protein: a new circulating biomarker associated with cardio-metabolic risk factors and carotid atherosclerosis. Eur Heart J 29:2156\u20132163. https:\/\/doi.org\/10.1093\/eurheartj\/ehn295","journal-title":"Eur Heart J"},{"key":"6461_CR27","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jacl.2015.12.012","volume":"10","author":"D Ibarretxe","year":"2016","unstructured":"Ibarretxe D, Girona J, Amig\u00f3 N, Plana N, Ferr\u00e9 R, Guaita S, Mallol R (2016) Impact of epidermal fatty acid binding protein on 2D-NMR-assessed atherogenic dyslipidemia and related disorders. J Clin Lipidol 10:330\u2013338. https:\/\/doi.org\/10.1016\/j.jacl.2015.12.012","journal-title":"J Clin Lipidol"},{"key":"6461_CR28","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jaad.2017.04.1133","volume":"77","author":"MJM Rodriguez-Zuniga","year":"2017","unstructured":"Rodriguez-Zuniga MJM, Garcia-Perdomo HA (2017) Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol 77:657\u2013666. https:\/\/doi.org\/10.1016\/j.jaad.2017.04.1133","journal-title":"J Am Acad Dermatol"},{"key":"6461_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/ijms19010058","volume":"19","author":"L Puig","year":"2018","unstructured":"Puig L (2018) Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. Int J Mol Sci 19:58. https:\/\/doi.org\/10.3390\/ijms19010058","journal-title":"Int J Mol Sci"},{"key":"6461_CR30","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/archinte.167.15.1670","volume":"167","author":"AR Setty","year":"2007","unstructured":"Setty AR, Curhan G, Choi HK (2007) Obesity, waist circumference, weight change, and the risk of psoriasis in women: nurses\u2019 health study II. Arch Intern Med 167:1670\u20131675. https:\/\/doi.org\/10.1001\/archinte.167.15.1670","journal-title":"Arch Intern Med"},{"key":"6461_CR31","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1016\/j.jid.2017.07.822","volume":"137","author":"I Snekvik","year":"2017","unstructured":"Snekvik I, Smith CH, Nilsen TIL, Langan SM, Modalsli RPR, Saunes M (2017) Obesity, waist circumference, weight change, and risk of incident psoriasis: prospective data from the HUNT study. J Invest Dermatol 137:2484\u20132490. https:\/\/doi.org\/10.1016\/j.jid.2017.07.822","journal-title":"J Invest Dermatol"},{"key":"6461_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/bjd.16885","volume":"180","author":"I Snekvik","year":"2019","unstructured":"Snekvik I, Nilsen TIL, Romundstad PR, Saunes M (2019) Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT Study, Norway. Br J Dermatol 180:94\u201399. https:\/\/doi.org\/10.1111\/bjd.16885","journal-title":"Br J Dermatol"},{"key":"6461_CR33","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.immuni.2015.04.016","volume":"42","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Li Q, Rao E, Sun Y, Grossmann ME, Morris RJ, Cleary MP, Li B (2015) Epidermal fatty acid binding protein promotes skin inflammation induced by high-fat diet. Immunity 42:953\u2013964. https:\/\/doi.org\/10.1016\/j.immuni.2015.04.016","journal-title":"Immunity"},{"key":"6461_CR34","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1107\/S1399004713026795","volume":"70","author":"B Sanson","year":"2014","unstructured":"Sanson B, Wang T, Sun J, Wang L, Kaczocha M, Ojima I, Deutsch D, Li H (2014) Crystallographic study of FABP5 as an intracellular endocannabinoid transporter. Acta Crystallogr D Biol Crystallogr 70:290\u2013298. https:\/\/doi.org\/10.1107\/S1399004713026795","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"6461_CR35","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.3892\/mmr.2014.2136","volume":"9","author":"S Qin","year":"2014","unstructured":"Qin S, Wen J, Bai XC, Chen TY, Zheng RC, Zhou GB, Ma J et al (2014) Endogenous n-3 polyunsaturated fatty acids protect against imiquimod-induced psoriasis-like inflammation via the IL-17\/IL-23 axis. Mol Med Rep 9:2097\u20132104. https:\/\/doi.org\/10.3892\/mmr.2014.2136","journal-title":"Mol Med Rep"},{"key":"6461_CR36","doi-asserted-by":"publisher","first-page":"e81318","DOI":"10.1371\/journal.pone.0081318","volume":"8","author":"S Ishimura","year":"2013","unstructured":"Ishimura S, Furuhashi M, Watanabe Y, Hoshina K, Fuseya T, Mita T, Okazaki Y et al (2013) Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS ONE 8:e81318. https:\/\/doi.org\/10.1371\/journal.pone.0081318","journal-title":"PLoS ONE"},{"key":"6461_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.5114\/ada.2020.96109","volume":"37","author":"A Owczarczyk-Saczonek","year":"2020","unstructured":"Owczarczyk-Saczonek A, Czerwi\u0144ska J, Orylska M, Placek W (2020) Effect of methotrexate treatment on the expression of epidermal fatty acid binding protein (E-FABP) and apolipoproteins in patients with psoriasis. Postepy Dermatol Alergol 37:401\u2013406. https:\/\/doi.org\/10.5114\/ada.2020.96109","journal-title":"Postepy Dermatol Alergol"},{"key":"6461_CR38","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.1463-1326.2007.00717.x","volume":"9","author":"DG Haider","year":"2007","unstructured":"Haider DG, Schindler K, Bohdjalian A, Prager G, Luger A, Wolzt M, Ludvik B (2007) Plasma adipocyte and epidermal fatty acid binding protein is reduced after weight loss in obesity. Diabetes Obes Metab 9:761\u2013763. https:\/\/doi.org\/10.1111\/j.1463-1326.2007.00717.x","journal-title":"Diabetes Obes Metab"},{"key":"6461_CR39","doi-asserted-by":"publisher","first-page":"e3491","DOI":"10.7759\/cureus.3491","volume":"10","author":"HA Alotaibi","year":"2018","unstructured":"Alotaibi HA (2018) Effect of weight loss on psoriasis: a review of clinical trials. Cureus 10:e3491. https:\/\/doi.org\/10.7759\/cureus.3491","journal-title":"Cureus"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06461-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-021-06461-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06461-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T05:12:33Z","timestamp":1625548353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-021-06461-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["6461"],"URL":"https:\/\/doi.org\/10.1007\/s11033-021-06461-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-101777\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-41783\/v1","asserted-by":"object"}]},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"30 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the study involving human participants were in accordance with the ethical standards of the Bioethical Committee of Medical University of Bia\u0142ystok and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards (permission nr R-I-002\/53\/2018). Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}